Emilia Barańska-Bała, Paulina Małachowska, Agnieszka Koper, Sławomir Wileński, Krzysztof Koper
{"title":"The impact of primary radical treatment on the effectiveness and safety of systemic treatment with ribociclib in female patients with advanced breast cancer","authors":"Emilia Barańska-Bała, Paulina Małachowska, Agnieszka Koper, Sławomir Wileński, Krzysztof Koper","doi":"10.5603/mrj.97119","DOIUrl":"https://doi.org/10.5603/mrj.97119","url":null,"abstract":"","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134909375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The development of malaria vaccine: a beacon of hope?","authors":"Moyinoluwa Joshua Oladoye, Chinelo Geraldine Ikele","doi":"10.5603/mrj.97178","DOIUrl":"https://doi.org/10.5603/mrj.97178","url":null,"abstract":"","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135730132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mateusz Raniewicz, Maciej Dubaj, Karol Bigosiński, Aleksandra Dembowska, Małgorzata Mitura-Lesiuk
Acute lymphoblastic leukaemia (ALL) is the most common malignancy among children. It originates from over-proliferating immature lymphoid cells called lymphoblasts. Modern genetic studies have shown that the aetiology of ALL is correlated with numerous chromosomal aberrations, including activating mutation of the JAK/STAT pathway. This pathway is responsible for regulating the transmission of signals from extracellular cytokines to the nucleus of cells, regulating their growth, differentiation and immune response. With proper patient diagnosis, it is possible to correctly classify the genetic subtypes of ALL, allowing more effective therapies to be introduced. The following study presents the importance of genetic diagnosis for the treatment of a paediatric patient with ALL with the above mutation in the genome.
{"title":"Importance of genetic diagnosis for treatment and prognosis in acute lymphoblastic leukaemia (ALL) — a case report","authors":"Mateusz Raniewicz, Maciej Dubaj, Karol Bigosiński, Aleksandra Dembowska, Małgorzata Mitura-Lesiuk","doi":"10.5603/mrj.96967","DOIUrl":"https://doi.org/10.5603/mrj.96967","url":null,"abstract":"Acute lymphoblastic leukaemia (ALL) is the most common malignancy among children. It originates from over-proliferating immature lymphoid cells called lymphoblasts. Modern genetic studies have shown that the aetiology of ALL is correlated with numerous chromosomal aberrations, including activating mutation of the JAK/STAT pathway. This pathway is responsible for regulating the transmission of signals from extracellular cytokines to the nucleus of cells, regulating their growth, differentiation and immune response. With proper patient diagnosis, it is possible to correctly classify the genetic subtypes of ALL, allowing more effective therapies to be introduced. The following study presents the importance of genetic diagnosis for the treatment of a paediatric patient with ALL with the above mutation in the genome.","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135853779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marta Głuchowska, Łukasz Gawlik, Azita Razaei, Marcin Gregorczyk, Piotr Jagodowski, Paweł Wróbel
Focal segmental glomerular sclerosis is a pattern of histological damage of the kidney. The most common clinical manifestation is proteinuria, however, it can frequently progress to full nephrotic syndrome. Glucocorticosteroids are the first line of treatment and, in case of resistance, calcineurin inhibitors are used. In some patients, despite treatment, focal segmental glomerular sclerosis leads to end-stage renal disease, in which organ transplantation is the only therapeutic option. In several cases, relapse occurs in the transplanted organ. The following paper presents a case report of a patient treated for focal segmental glomerular sclerosis since the age of 21, who developed end-stage renal failure after seven years of disease despite immunosuppressive treatment. Although there was a significant risk of recurrence, it was decided to transplant a kidney from a family donor — the patient’s mother. From about one week after transplantation, progressive deterioration of graft function was observed.
{"title":"Graft loss from a living donor due to flash recurrence of focal segmental glomerular sclerosis — case report","authors":"Marta Głuchowska, Łukasz Gawlik, Azita Razaei, Marcin Gregorczyk, Piotr Jagodowski, Paweł Wróbel","doi":"10.5603/mrj.96872","DOIUrl":"https://doi.org/10.5603/mrj.96872","url":null,"abstract":"Focal segmental glomerular sclerosis is a pattern of histological damage of the kidney. The most common clinical manifestation is proteinuria, however, it can frequently progress to full nephrotic syndrome. Glucocorticosteroids are the first line of treatment and, in case of resistance, calcineurin inhibitors are used. In some patients, despite treatment, focal segmental glomerular sclerosis leads to end-stage renal disease, in which organ transplantation is the only therapeutic option. In several cases, relapse occurs in the transplanted organ. The following paper presents a case report of a patient treated for focal segmental glomerular sclerosis since the age of 21, who developed end-stage renal failure after seven years of disease despite immunosuppressive treatment. Although there was a significant risk of recurrence, it was decided to transplant a kidney from a family donor — the patient’s mother. From about one week after transplantation, progressive deterioration of graft function was observed.","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135854380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Piotr Pawłucki, Łukasz Domagalski, Michał Jakub Sekuła, Natalia Kaleta, Anna Maciak, Katarzyna Kopeć, Paulina Cuper
Obstructive sleep apnea (OSA) is a common disease in today's society and may affect even more of the population in the near future. Ailments and complications of OSA result from a decrease in the muscle tone of the soft palate, which causes shallow breathing or complete apnea. The consequences of such episodes may be the development of arterial hypertension, the occurrence of cardiac arrhythmias, and also a deterioration in the quality of life. Diagnosis is based on polysomnography in people with suspected OSA. Continuous Positive Airway Pressure (CPAP) therapy is the most effective treatment for OSA. We present a case series in which patients with OSA risk factors and nocturnal pauses in Holter ECG monitoring (HEM) were diagnosed due to suspected OSA. In the polysomnographic test, severe OSA was diagnosed and CPAP therapy was introduced. Follow-up HEM performed during treatment showed complete resolution or significant reduction in the number and length of nocturnal pauses. Based on the case series, current medical knowledge and guidelines for pacemaker implantation, we concluded that in the event of pauses in the HEM, the diagnosis of OSA should be considered in each patient, especially if the pauses occur mainly at night and the patient is at high risk of OSA. Such a procedure may protect the patient from serious complications related to the pacemaker implantation. It should be emphasized, however, that CPAP therapy requires close cooperation of the patient, because it brings effects only when it is used for each sleep.
{"title":"Diagnosis and treatment of obstructive sleep apnea in patients with pauses in Holter ECG monitoring: case series","authors":"Piotr Pawłucki, Łukasz Domagalski, Michał Jakub Sekuła, Natalia Kaleta, Anna Maciak, Katarzyna Kopeć, Paulina Cuper","doi":"10.5603/mrj.96809","DOIUrl":"https://doi.org/10.5603/mrj.96809","url":null,"abstract":"Obstructive sleep apnea (OSA) is a common disease in today's society and may affect even more of the population in the near future. Ailments and complications of OSA result from a decrease in the muscle tone of the soft palate, which causes shallow breathing or complete apnea. The consequences of such episodes may be the development of arterial hypertension, the occurrence of cardiac arrhythmias, and also a deterioration in the quality of life. Diagnosis is based on polysomnography in people with suspected OSA. Continuous Positive Airway Pressure (CPAP) therapy is the most effective treatment for OSA. We present a case series in which patients with OSA risk factors and nocturnal pauses in Holter ECG monitoring (HEM) were diagnosed due to suspected OSA. In the polysomnographic test, severe OSA was diagnosed and CPAP therapy was introduced. Follow-up HEM performed during treatment showed complete resolution or significant reduction in the number and length of nocturnal pauses. Based on the case series, current medical knowledge and guidelines for pacemaker implantation, we concluded that in the event of pauses in the HEM, the diagnosis of OSA should be considered in each patient, especially if the pauses occur mainly at night and the patient is at high risk of OSA. Such a procedure may protect the patient from serious complications related to the pacemaker implantation. It should be emphasized, however, that CPAP therapy requires close cooperation of the patient, because it brings effects only when it is used for each sleep.","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135855413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Monika Paskudzka, Aleksandra Kumorek, Aleksandra Kijak, Marcin Śmiarowski, Dagmara Kogut, Milena Małecka-Giełdowska, Olga Ciepiela
Introduction: Infection with the SARS-CoV-2 virus can lead to the development of COVID-19. Currently, more than 700 million people worldwide have been diagnosed with COVID-19, of which nearly 7 million have died from the severe course of the disease. Recent reports suggest that patients with blood group A are most at risk of developing COVID-19, and people with natural anti-A antibodies (especially those with blood type 0) have a milder course of the disease. This study aimed to assess the humoral response to infection with SARS-CoV-2 depending on the patient’s blood type. Material and methods: The study group consisted of 147 patients with confirmed previous COVID-19 (convalescents) and 147 individuals who declared no previous infection with SARS-CoV-2. All enrolled subjects were blood donors registered at Regional Blood Center. The concentration of SARS-CoV-2 anti-nucleocapsid antibodies was determined in the serum of the patients using the Elecsys Anti-SARS-CoV-2 test. The blood group was determined by a manual method using anti-A, anti-B, and anti-D monoclonal sera and A, B, and 0 standard red blood cells (RBC). Results and conclusions: Based on anti-SARS-CoV-2 detection 68 people who denied contact with SARS-CoV-2 had previous asymptomatic infection. Blood type distribution differed between the asymptomatic convalescents and the declared convalescents, p = 0.0013. People with Arh–, BRh+, BRh–, and 0Rh– blood type were more often asymptomatically infected. Moreover, the Rh- subjects more often didn’t know about the previous infection than those with Rh+, p = 0.0012. It seems that subjects with Rh– blood type have a significantly milder course of disease than Rh+.
{"title":"Rh negativity seems to predispose to a milder COVID-19 course","authors":"Monika Paskudzka, Aleksandra Kumorek, Aleksandra Kijak, Marcin Śmiarowski, Dagmara Kogut, Milena Małecka-Giełdowska, Olga Ciepiela","doi":"10.5603/mrj.96960","DOIUrl":"https://doi.org/10.5603/mrj.96960","url":null,"abstract":"Introduction: Infection with the SARS-CoV-2 virus can lead to the development of COVID-19. Currently, more than 700 million people worldwide have been diagnosed with COVID-19, of which nearly 7 million have died from the severe course of the disease. Recent reports suggest that patients with blood group A are most at risk of developing COVID-19, and people with natural anti-A antibodies (especially those with blood type 0) have a milder course of the disease. This study aimed to assess the humoral response to infection with SARS-CoV-2 depending on the patient’s blood type. Material and methods: The study group consisted of 147 patients with confirmed previous COVID-19 (convalescents) and 147 individuals who declared no previous infection with SARS-CoV-2. All enrolled subjects were blood donors registered at Regional Blood Center. The concentration of SARS-CoV-2 anti-nucleocapsid antibodies was determined in the serum of the patients using the Elecsys Anti-SARS-CoV-2 test. The blood group was determined by a manual method using anti-A, anti-B, and anti-D monoclonal sera and A, B, and 0 standard red blood cells (RBC). Results and conclusions: Based on anti-SARS-CoV-2 detection 68 people who denied contact with SARS-CoV-2 had previous asymptomatic infection. Blood type distribution differed between the asymptomatic convalescents and the declared convalescents, p = 0.0013. People with Arh–, BRh+, BRh–, and 0Rh– blood type were more often asymptomatically infected. Moreover, the Rh- subjects more often didn’t know about the previous infection than those with Rh+, p = 0.0012. It seems that subjects with Rh– blood type have a significantly milder course of disease than Rh+.","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136014517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Multiple new therapeutic options for the treatment of obesity","authors":"Julia M. Umińska","doi":"10.5603/mrj.97463","DOIUrl":"https://doi.org/10.5603/mrj.97463","url":null,"abstract":"","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135131856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zuzanna Głowacka, Paulina Ryszka, Lidia Wydeheft, Klaudyna Grzelakowska, Michał Kasprzak, Jacek Kubica
Introduction: Widespread immunization is critical to bringing the COVID-19 pandemic to an end. The objective of this cross-sectional data analysis was to investigate the impact of vaccination on the frequency of COVID-19 occurrence and the presence of its symptoms and clinical presentations. Material and methods: This was a retrospective, cross-sectional study, analysing medical records of patients hospitalized at the Dr Antoni Jurasz University Hospital No. 1 in Bydgoszcz in the years 2019–2021. The analysis considered age, sex, vaccination status, the result of the reverse transcription polymerase chain reaction (RT-PCR) test for the detection of SARS-CoV-2 RNA, and disease symptoms and clinical presentations in accordance with ICD-10 codes. Results: The study group consisted of 27,209 patients. There were 1,393 persons (5.12%) who tested positive for COVID-19. The vaccinated patients accounted for 17.3% (n = 4,704). Those vaccinated were significantly less likely to test positive for COVID-19 (3.93% vs. 5.38%; p < 0.0001). Among unvaccinated patients with a positive test result for COVID-19, symptoms and/or clinical presentations occurred in 359 study participants (29.72%), while in vaccinated COVID-19-positive patients only in 49 persons (26.49%). The symptoms that occurred in both vaccinated and unvaccinated patients were mainly respiratory and circulatory. The most common clinical presentation, both in the group of vaccinated and unvaccinated patients, was viral pneumonia, not elsewhere classified (J12), which occurred in 17.30% and 9.19% of patients, respectively (p = 0.005). Other symptoms and clinical presentations showing a statistically significant difference in the frequency of occurrence between the groups were pneumonia in diseases classified elsewhere (J17; p = 0.019) and abnormalities of breathing (R06; p = 0.001). Conclusions: Vaccination against COVID-19 protects against symptomatic disease.
{"title":"COVID-19 occurrence and symptoms depending on vaccination status: a retrospective single-centre analysis of 27,209 patients","authors":"Zuzanna Głowacka, Paulina Ryszka, Lidia Wydeheft, Klaudyna Grzelakowska, Michał Kasprzak, Jacek Kubica","doi":"10.5603/mrj.96746","DOIUrl":"https://doi.org/10.5603/mrj.96746","url":null,"abstract":"Introduction: Widespread immunization is critical to bringing the COVID-19 pandemic to an end. The objective of this cross-sectional data analysis was to investigate the impact of vaccination on the frequency of COVID-19 occurrence and the presence of its symptoms and clinical presentations. Material and methods: This was a retrospective, cross-sectional study, analysing medical records of patients hospitalized at the Dr Antoni Jurasz University Hospital No. 1 in Bydgoszcz in the years 2019–2021. The analysis considered age, sex, vaccination status, the result of the reverse transcription polymerase chain reaction (RT-PCR) test for the detection of SARS-CoV-2 RNA, and disease symptoms and clinical presentations in accordance with ICD-10 codes. Results: The study group consisted of 27,209 patients. There were 1,393 persons (5.12%) who tested positive for COVID-19. The vaccinated patients accounted for 17.3% (n = 4,704). Those vaccinated were significantly less likely to test positive for COVID-19 (3.93% vs. 5.38%; p < 0.0001). Among unvaccinated patients with a positive test result for COVID-19, symptoms and/or clinical presentations occurred in 359 study participants (29.72%), while in vaccinated COVID-19-positive patients only in 49 persons (26.49%). The symptoms that occurred in both vaccinated and unvaccinated patients were mainly respiratory and circulatory. The most common clinical presentation, both in the group of vaccinated and unvaccinated patients, was viral pneumonia, not elsewhere classified (J12), which occurred in 17.30% and 9.19% of patients, respectively (p = 0.005). Other symptoms and clinical presentations showing a statistically significant difference in the frequency of occurrence between the groups were pneumonia in diseases classified elsewhere (J17; p = 0.019) and abnormalities of breathing (R06; p = 0.001). Conclusions: Vaccination against COVID-19 protects against symptomatic disease.","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136377728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Accurate risk stratification is an important element of management in patients with advanced heart failure (adHF). Objectives: We aimed to determine factors associated with three–year mortality in patients with adHF who underwent qualification for heart transplantation. Material and methods: We retrospectively analyzed the data of 417 consecutive adult patients with adHF hospitalized in the Cardiology Department between 2011 and 2017. We included patients with New York Heart Association classes III–IV with at least two episodes of proven congestion requiring high-dose intravenous diuretics in the last 12 months. Exclusion criteria were acute HF, inotropic support, any previous heart surgery, inflammatory diseases, chronic kidney and liver disease, severe obstructive pulmonary disease and hematologic, autoimmune or neoplastic diseases. We analysed prognostic value of the model for end-stage liver disease (MELD), which reflects multiorgan dysfunction. The primary endpoint was death during three years of follow-up. Results: In the overall population of 293 patients the median age was 56 (51–61) years, and 92.8% of the patients were male. During the follow-up period, 160 patients reached the primary endpoint. The MELD-XI score hazard ratio (HR) 1.197; 95% CI (confidence interval) (1.131–1.267), p < 0.001), PLR value [HR 1.100; 95% CI (1.080–1.130), p < 0.001], uric acid [HR 1.013; 95% CI (1.002–1.024), p = 0.0169] and sodium HR 1.079; 95% CI (1.044–1.115), p < 0.001] serum concentrations were independent factors of three–year mortality. Conclusions: Higher MELD-XI scores and PLR values as well as higher uric acid and lower serum sodium concentrations are associated with worse outcomes in patients with adHF.
准确的风险分层是晚期心力衰竭(adHF)患者管理的重要因素。目的:我们旨在确定接受心脏移植资格的adHF患者三年死亡率的相关因素。材料与方法:回顾性分析2011年至2017年在心内科连续住院的417例adHF成人患者的资料。我们纳入了纽约心脏协会III-IV级的患者，在过去12个月内至少有两次经证实的充血需要大剂量静脉利尿剂。排除标准为急性心衰、肌力支持、任何既往心脏手术、炎症性疾病、慢性肾脏和肝脏疾病、严重阻塞性肺疾病、血液病、自身免疫性或肿瘤疾病。我们分析了反映多器官功能障碍的终末期肝病(MELD)模型的预后价值。主要终点是3年随访期间的死亡。结果:293例患者中位年龄为56(51 ~ 61)岁，男性占92.8%。在随访期间，160例患者达到了主要终点。95% CI(置信区间)(1.131-1.267)，p <0.001)， PLR值[HR 1.100;95% CI (1.080-1.130)， p <0.001]，尿酸[HR 1.013;95% CI (1.002-1.024)， p = 0.0169]， HR 1.079;95% CI (1.044-1.115)， p <0.001]血清浓度是3年死亡率的独立因素。
{"title":"The model for end-stage liver disease excluding international normalized ratio (MELD-XI) predicts three-year mortality in patients with advanced heart failure","authors":"Kamila Kurkiewicz-Sawczak, Zofia Gierlotka, Mariusz Gąsior, Bożena Szyguła-Jurkiewicz","doi":"10.5603/mrj.97134","DOIUrl":"https://doi.org/10.5603/mrj.97134","url":null,"abstract":"Introduction: Accurate risk stratification is an important element of management in patients with advanced heart failure (adHF). Objectives: We aimed to determine factors associated with three–year mortality in patients with adHF who underwent qualification for heart transplantation. Material and methods: We retrospectively analyzed the data of 417 consecutive adult patients with adHF hospitalized in the Cardiology Department between 2011 and 2017. We included patients with New York Heart Association classes III–IV with at least two episodes of proven congestion requiring high-dose intravenous diuretics in the last 12 months. Exclusion criteria were acute HF, inotropic support, any previous heart surgery, inflammatory diseases, chronic kidney and liver disease, severe obstructive pulmonary disease and hematologic, autoimmune or neoplastic diseases. We analysed prognostic value of the model for end-stage liver disease (MELD), which reflects multiorgan dysfunction. The primary endpoint was death during three years of follow-up. Results: In the overall population of 293 patients the median age was 56 (51–61) years, and 92.8% of the patients were male. During the follow-up period, 160 patients reached the primary endpoint. The MELD-XI score hazard ratio (HR) 1.197; 95% CI (confidence interval) (1.131–1.267), p < 0.001), PLR value [HR 1.100; 95% CI (1.080–1.130), p < 0.001], uric acid [HR 1.013; 95% CI (1.002–1.024), p = 0.0169] and sodium HR 1.079; 95% CI (1.044–1.115), p < 0.001] serum concentrations were independent factors of three–year mortality. Conclusions: Higher MELD-XI scores and PLR values as well as higher uric acid and lower serum sodium concentrations are associated with worse outcomes in patients with adHF.","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135209385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：